InvestorsHub Logo

CrashOverride

12/08/22 4:06 PM

#545996 RE: flipper44 #545993

Yes it's been determined that small dose Temodar does not impair T cells. He could help further that research instead he accuses the trial authors and company of having a flawed design. He's saying the trial effectively does not help GBM patients though he didn't have the balls to say that outright.

Very childish.

Very passive aggressive behavior from somebody not at the cutting edge.

Reminds me of Intel before AMD launched their Zen chips. They thought their incumbency in the market granted themselves a durable competitive advantage then they stopped innovating. They then lost marketshare.

Once approved GBM patients are not choosing Optune or Temodar over DCVax!
Bullish
Bullish

Zadie420

12/08/22 6:05 PM

#546071 RE: flipper44 #545993

Great post, flipper. I am surprised why no good doctor pick up on this and run small if this criteria holds. If this true , then we could have increase OS percentage to a level that there would be no room for discussion. You got this right.

newman2021

12/08/22 7:11 PM

#546105 RE: flipper44 #545993

CVM's multikine therapy did better in a subgroup where there was no chemo involved.